rallydemand

274 results found.

Top Stocks matching your search for "rally demand"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

02/1002/1502/2102/2403/0103/0603/0903/1403/1703/22
RAD

Rite Aid Corp.

-35.07%

$3.65 - $2.37

Feb 8th 2023 - Mar 22nd 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 19, 2023

I wanna bless $ODP and $RAD = For having the best ... See more

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
XPEV

XPeng Inc - ADR

-4.16%

$10.34 - $9.91

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 20, 2023

$NIO $XPEV $LI $LCID lifted ,parts to make the ve... See more

Jan, 18, 2023

Auto sales managed to maintain momentum last year ... See more

Image with triangles

Divihomes is Now Live

A new search platform that matches you with the best home improvement service providers in your area.

Instant Search & Match with Top Contractors

Instant Communication with Local Contractors

Phone Image with DiviHomes website

Millions of Unbiased User Reviews

100% Free Quotes from Top-Notch Contractors

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
NOTV

Inotiv Inc

-40.66%

$7.92 - $4.70

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 11, 2023

$NOTV, low supply, high demand = great pricing power.

Jan, 11, 2023

Although we were impacted by the NHP supply issue ... See more

RAD

Rite Aid Corp.

-35.07%

$3.65 - $2.37

Feb 8th 2023 - Mar 22nd 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 19, 2023

I wanna bless $ODP and $RAD = For having the best supplies for me to dance once again . https://www.instagram.com/p/CngIxxHKiLu/

XPEV

XPeng Inc - ADR

-4.16%

$10.34 - $9.91

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 20, 2023

$NIO $XPEV $LI $LCID lifted ,parts to make the vehicles to reach demand, and battery 🔋 cost 💲 down !

Jan, 18, 2023

Auto sales managed to maintain momentum last year even in the face of COVID resurgences, commodity inflation, chip crunch and supply chain snarls.

Nov, 11, 2022

These features will drive the demand for G9.

Nov, 2, 2022

J.P. Morgan Remains Bullish on Chinese EV Stocks Despite ‘Flattish Demand’: NIO and XPEV in Focus 🥂 $XPEV $NIO $TSLA https://www.tipranks.com/news/article/j-p-morgan-remains-bullish-on-chinese-ev-stocks-despite-flattish-demand-nio-and-xpev-in-focus

Nov, 2, 2022

It has cheap energy supply which makes it competitive.

Nov, 2, 2022

J.P. Morgan Remains Bullish on Chinese EV Stocks Despite ‘Flattish Demand’: NIO and XPEV in Focus https://www.tipranks.com/news/article/j-p-morgan-remains-bullish-on-chinese-ev-stocks-despite-flattish-demand-nio-and-xpev-in-focus $NIO $XPEV

Oct, 24, 2022

ten folds in demand!!!!

Oct, 24, 2022

Lower price will expand the demand (pie), not shrinking it.

Oct, 24, 2022

They handled the supply chain disruption beautifully during the pandemic and have been marketing aggressively.

NOTV

Inotiv Inc

-40.66%

$7.92 - $4.70

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 11, 2023

$NOTV, low supply, high demand = great pricing power.

Jan, 11, 2023

Although we were impacted by the NHP supply issue in Q1, we believe the business is well positioned to achieve above market revenue growth rates and expansion in margins.

Dec, 20, 2022

Good leadership, good company, and solid demand for their services.

Nov, 25, 2022

Supply chain will stay intact.

Nov, 18, 2022

Supply chain is not broken.

Nov, 18, 2022

Inotiv's supply chain has not been broken.

Nov, 17, 2022

Importantly, Envigo has another key advantage in fulfilling the niche, other than access to cheap supply: a unique ability to humanely transport, board, and quaranteen the animals.

Nov, 2, 2022

Also a good read-thru for $PSNL, who expanded capacity recently and launched a new site to match growing demand from biopharma.